End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
21.49 CNY | +2.82% | +4.22% | -12.29% |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
Strengths
- Its core activity has a significant growth potential and sales are expected to surge, according to Standard & Poor's' forecast. Indeed, those may increase by -100% by 2026.
- The company's profit outlook over the next few years is a strong asset.
- The company's attractive earnings multiples are brought to light by a P/E ratio at 11.87 for the current year.
- The company's share price in relation to its net book value makes it look relatively cheap.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
Ratings chart - Surperformance
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-12.29% | 785M | - | ||
-30.75% | 3.08B | B- | ||
-15.97% | 2.53B | C+ | ||
+18.11% | 2.47B | - | A- | |
+7.78% | 2.1B | B | ||
-9.47% | 1.91B | - | ||
-0.56% | 1.51B | B | ||
+2.24% | 1.34B | - | ||
+24.32% | 1.24B | C | ||
+3.86% | 1.13B | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 603301 Stock
- Ratings Zhende Medical Co., Ltd.